Novartis' newly acquired melanoma combo wins EU recommendation

Things are looking up for Novartis' ($NVS) recently acquired melanoma duo, Tafinlar and Mekinist. The pair, acquired from GlaxoSmithKline ($GSK) as part of a multibillion-dollar asset swap that closed earlier this year, has won a recommendation from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) as a combo treatment for BRAF V600 mutation-positive melanoma, the Swiss pharma giant said Friday. And on the other side of the pond, the FDA has granted it a priority review in the same indication. Release

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.